Background
Golimumab with trade name Simponi, is an FDA-approved drug for the treatment of Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Ulcerative Colitis (UC). It is a human IgG1κ monoclonal antibody that binds to Tumor Necrosis Factor alpha (TNF-alpha), thereby inhibiting the binding to TNFα receptors and subsequent generation of inflammatory cytokines. Antibodysystem Anti-Golimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Golimumab.